Premium
Immunization of Saimiri sciureus Monkeys with Plasmodium falciparum Merozoite Surface Protein‐3 and Glutamate‐Rich Protein Suggests that Protection is Related to Antibody Levels
Author(s) -
Carvalho L. J. M.,
Oliveira S. G.,
Theisen M.,
Alves F. A.,
Andrade M. C. R.,
Zanini G. M.,
Brígido M. C. O.,
Oeuvray C.,
Póvoa M. M.,
Muniz J. A. P. C.,
Druilhe P.,
DanielRibeiro C. T.
Publication year - 2004
Publication title -
scandinavian journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.934
H-Index - 88
eISSN - 1365-3083
pISSN - 0300-9475
DOI - 10.1111/j.0300-9475.2004.01409.x
Subject(s) - immunogenicity , merozoite surface protein , plasmodium falciparum , saimiri sciureus , antigen , virology , biology , antibody , adjuvant , immunization , immunology , malaria , malaria vaccine , squirrel monkey , neuroscience
The immunogenicity and protective efficacy of various antigen‐adjuvant formulations derived either from the merozoite‐surface protein‐3 (MSP‐3) or the glutamate‐rich protein (GLURP) of Plasmodium falciparum were evaluated in Saimiri sciureus monkeys. These proteins were selected for immunogenicity studies based primarily on their capacity of inducing an antibody‐dependent cellular inhibition effect on parasite growth. Some of the S. sciureus monkeys immunized with MSP‐3 212−380 ‐AS02 or GLURP 27−500 ‐alum were able to fully or partially control parasitaemia upon an experimental P. falciparum [Falciparum Uganda Palo Alto (FUP‐SP) strain] blood‐stage infection, and this protection was related to the prechallenge antibody titres induced. The data are indicative that MSP‐3 and GLURP can induce protective immunity against an experimental P. falciparum infection using adjuvants that are acceptable for human use and this should trigger further studies with those new antigens.